Evidence map›Paper›PMID 26327756›Full record

ReviewWorld journal of gastroenterology2015

Epidemiology of hepatitis C in Croatia in the European context.

Tatjana Vilibic-Cavlek, Jasmina Kucinar, Bernard Kaic, Maja Vilibic, Nenad Pandak, Ljubo Barbic, Vladimir Stevanovic, Jasmina Vranes

Open access · bronzeAbstract readReview
In one paragraph

Review in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. The role of inflammasome in chronic viral hepatitis.Frontiers in cellular and infection microbiology · 2024
    Review
  4. Review
  5. Article
  6. Review
  7. Hepatotropic viruses: Is Roma population at risk?World journal of gastroenterology · 2021
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Tatjana Vilibic-CavlekTatjana Vilibic-Cavlek, Department of Virology, Croatian National Institute of Public Health and School of Medicine University of Zagreb, Zagreb 10000, Croatia.
Jasmina KucinarTatjana Vilibic-Cavlek, Department of Virology, Croatian National Institute of Public Health and School of Medicine University of Zagreb, Zagreb 10000, Croatia.
Bernard KaicTatjana Vilibic-Cavlek, Department of Virology, Croatian National Institute of Public Health and School of Medicine University of Zagreb, Zagreb 10000, Croatia.
Maja VilibicTatjana Vilibic-Cavlek, Department of Virology, Croatian National Institute of Public Health and School of Medicine University of Zagreb, Zagreb 10000, Croatia.
Nenad PandakTatjana Vilibic-Cavlek, Department of Virology, Croatian National Institute of Public Health and School of Medicine University of Zagreb, Zagreb 10000, Croatia.
Ljubo BarbicTatjana Vilibic-Cavlek, Department of Virology, Croatian National Institute of Public Health and School of Medicine University of Zagreb, Zagreb 10000, Croatia.
Vladimir StevanovicTatjana Vilibic-Cavlek, Department of Virology, Croatian National Institute of Public Health and School of Medicine University of Zagreb, Zagreb 10000, Croatia.
Jasmina VranesTatjana Vilibic-Cavlek, Department of Virology, Croatian National Institute of Public Health and School of Medicine University of Zagreb, Zagreb 10000, Croatia.
University of Zagreb · HR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We analyzed prevalence, risk factors and hepatitis C virus (HCV) genotype distribution in different population groups in Croatia in the context of HCV epidemiology in Europe, with the aim to gather all existing information on HCV infection in Croatia which will be used to advise upon preventive measures. It is estimated that 35000-45000 of the Croatian population is chronically infected with HCV. Like in other European countries, there have been changes in the HCV epidemiology in Croatia over the past few decades. In some risk groups (polytransfused and hemodialysis patients), a significant decrease in the HCV prevalence was observed after the introduction of routine HCV screening of blood/blood products in 1992. Injecting drug users (IDUs) still represent a group with the highest risk for HCV infection with prevalence ranging from 29% to 65%. Compared to the prevalence in the Croatian general population (0.9%), higher prevalence rates were found in prison populations (8.3%-44%), human immunodeficiency virus-infected patients (15%), persons with high-risk sexual behavior (4.6%) and alcohol abusers (2.4%). Low/very low prevalence was reported in children and adolescents (0.3%) as well as in blood donors (0%-0.009%). In addition, distribution of HCV genotypes has changed due to different routes of transmission. In the general population, genotypes 1 and 3 are most widely distributed (60.4%-79.8% and 12.9%-47.9%, respectively). The similar genotype distribution is found in groups with high-risk sexual behavior. Genotype 3 is predominant in Croatian IDUs (60.5%-83.9%) while in the prison population genotypes 3 and 1 are equally distributed (52.4% and 47.6%). Data on HCV prevalence and risk factors for transmission are useful for implementation of preventive measures and HCV screening.

Indexed as

CroatiaGenotypeHepacivirusHepatitis CHumansMass ScreeningPrevalenceRisk FactorsCroatiaEuropeGenotypesHepatitis CSeroprevalence

Identifiers

PMID26327756
PMCPMC4548109
OpenAlexW1416735918

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.